Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Nature Medicine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8705854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

  1995cited by this paper
• Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

  1995cited by this paper
• Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

  1995cited by this paper
• Solvent exposure as a risk factor for Alzheimer's disease: a case-control study.

  1995cited by this paper
• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

  1995cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• A familial Alzheimer's disease locus on chromosome 1

  1995cited by this paper
• Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E.

  1995cited by this paper
• Candidate gene for the chromosome 1 familial Alzheimer's disease locus

  1995cited by this paper
• Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome

  1995cited by this paper
• Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

  1994cited by this paper
• Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

  1994cited by this paper
• Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.

  1994cited by this paper
• APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain.

  1994cited by this paper
• An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

  1994cited by this paper
• Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.

  1993cited by this paper
• Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?

  1993cited by this paper
• Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.

  1993cited by this paper
• Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease.

  1993cited by this paper
• Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.

  1993cited by this paper
• Characterization of beta-amyloid peptide from human cerebrospinal fluid.

  1993cited by this paper
• The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.

  1993cited by this paper
• Amyloid beta-peptide is produced by cultured cells during normal metabolism.

  1992cited by this paper
• Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

  1992cited by this paper
• A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

  1992cited by this paper
• Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

  1992cited by this paper
• Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

  1992cited by this paper
• Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

  1992cited by this paper
• A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.

  1991cited by this paper
• Molecular classification of Alzheimer's disease.

  1991cited by this paper
• The 717Val----Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups.

  1991cited by this paper
• Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene

  1991cited by this paper
• Mis-sense mutation Val----Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease.

  1991cited by this paper
• Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

  1991cited by this paper
• Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease.

  1991cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Abnormal metabolism of gamma-trace alkaline microprotein. The basic defect in hereditary cerebral hemorrhage with amyloidosis.

  1984cited by this paper

• The Icelandic Mutation in the Murine APP Gene, mAPPA673T, on Amyloid-β Plaque Burden in the 5×FAD Alzheimer Model.

  2026cites this paper
• Mitochondrial dysfunction and Ca2+ dysregulation in human iPSC-derived neurons carrying presenilin-1 mutation arise under stress via an MCU-1-independent mechanism

  2026cites this paper
• A synthetic nonapeptide, JAL-TA9, inhibits neuronal cytotoxicity caused by Aβ25-35 aggregation with proteolytic activity.

  2025cites this paper
• Unraveling the mystery of citrate transporters in Alzheimer's disease: An updated review.

  2025cites this paper
• Molecular insight into cross-interaction between amyloid β isoforms and its effect on aggregation pathways

  2025cites this paper
• Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency

  2025cites this paper
• Neuron-Astrocyte Interactions in Aging and Alzheimer's Disease: Dysregulation of Amyloid Precursor Protein.

  2025cites this paper
• Aducanumab Binding to Aβ1–42 Fibrils Alters Dynamics of the N-Terminal Tail While Preserving the Fibril Core

  2025cites this paper
• Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels

  2025cites this paper
• Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer's Disease.

  2025cites this paper
• Older Amyloid Beta as a Candidate Blood Biomarker of Early Cognitive Decline in the Elderly—A Preliminary Study

  2025cites this paper
• Amyloid Protein-Induced Remodeling of Morphometry and Nanomechanics in Human Platelets

  2025cites this paper
• Triggering ferroptosis in neurodegenerative diseases.

  2025cites this paper
• Phenotypic variability in early-onset dementia segregating with a novel APP (p.I718M) variant

  2025cites this paper
• The Spectrum of Genetic Risk in Alzheimer Disease

  2025cites this paper
• Selective association of EEG microstates with clinical symptoms and mutation status in monogenic Alzheimer disease

  2025cites this paper
• A Randomized Clinical Trial Reveals Effects of Mindfulness and Slow Breathing on Plasma Amyloid Beta Levels

  2025cites this paper
• The underlying role of pericyte-related cerebral lymphatic microcirculation dysfunction in cerebral small vessel disease.

  2025cites this paper
• The p3 peptides (Aβ17-40/42) rapidly form amyloid fibrils that cross-seed with full-length Aβ

  2025cites this paper
• Spectrum of γ-Secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes

  2025cites this paper
• Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases

  2025cites this paper
• Fluid biomarkers of vascular cognitive Impairment: From vascular pathophysiology to potential clinical applications.

  2025cites this paper
• Improved Oral Bioavailability and Brain Distribution of Hesperidin via Cochleate Formulation: Statistical Optimization and Pharmacokinetic Study

  2025cites this paper
• γ-Secretase modulator resistance of an aggressive Alzheimer-causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds

  2025cites this paper
• Impairment of Tricarboxylic Acid Cycle (TCA) Cycle in Alzheimer's Disease: Mechanisms, Implications, and Potential Therapies

  2025cites this paper
• Molecular mechanism of phosphorylation-mediated impacts on the conformation dynamics of ligand-bound BACE1 probed by Gaussian accelerated molecular dynamics.

  2025cites this paper
• The novel role of Kallistatin in linking metabolic syndromes and cognitive memory deterioration by inducing amyloid-β plaques accumulation and tau protein hyperphosphorylation

  2025cites this paper
• Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations

  2025cites this paper
• Aducanumab binding to Aβ1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core.

  2025cites this paper
• Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

  2025cites this paper
• The Icelandic mutation APPA673T on amyloid-β plaque burden in the 5xFAD Alzheimer model

  2025cites this paper
• Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?

  2024cites this paper
• Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease

  2024cites this paper
• Behavioral and Metabolic Effects of ABCG4 KO in the APPswe,Ind (J9) Mouse Model of Alzheimer’s Disease

  2024cites this paper
• PSEN2 Mutations May Mimic Frontotemporal Dementia: Two New Case Reports and a Review

  2024cites this paper
• Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems.

  2024cites this paper
• The Amyloid Cascade Hypothesis: A Conclusion in Search of Support.

  2024cites this paper
• Single-Molecule Characterization of Heterogeneous Oligomer Formation during Co-Aggregation of 40- and 42-Residue Amyloid-β.

  2024cites this paper
• C. elegans: a prominent platform for modeling and drug screening in neurological disorders

  2024cites this paper
• Lutein from Chicken Eggs Prevents Amyloid β-Peptide Aggregation In Vitro and Amyloid β-Induced Inflammation in Human Macrophages (THP-1)

  2024cites this paper
• New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases

  2024cites this paper
• The CHD family chromatin remodeling enzyme, Kismet, promotes both clathrin-mediated and activity-dependent bulk endocytosis

  2024cites this paper
• A multi-looping chromatin signature predicts dysregulated gene expression in neurons with familial Alzheimer’s disease mutations

  2024cites this paper
• Human iPSC-derived retinal organoids develop robust Alzheimer’s disease neuropathology

  2024cites this paper
• A Brief Review on Caenorhabditis elegans Role in Modelling Neurodegenerative Disease.

  2024cites this paper
• An Overview of the Genes and Biomarkers in Alzheimer's Disease.

  2024influential citation
• High-intensity interval training combined with cannabidiol supplementation improves cognitive impairment by regulating the expression of apolipoprotein E, presenilin-1, and glutamate proteins in a rat model of amyloid β-induced Alzheimer’s disease

  2024cites this paper
• Microglial APOE3 Christchurch protects neurons from Tau pathology in a human iPSC-based model of Alzheimer’s disease

  2024cites this paper
• Alzheimer’s disease and clinical trials

  2024cites this paper
• Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis

  2024cites this paper
• An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer’s Mouse Model

  2024cites this paper
• The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential

  2024cites this paper
• Zebrafish Experimental Animal Models for AD: A Comprehensive Review.

  2024cites this paper
• Pathophysiologic abnormalities in transgenic mice carrying the Alzheimer disease PSEN1 Δ440 mutation.

  2024cites this paper
• Rosemarinic Acid-Induced Destabilization of Aβ Peptides: Insights from Molecular Dynamics Simulations

  2024cites this paper
• Role of PIM Kinase Inhibitor in the Treatment of Alzheimer’s Disease

  2024cites this paper
• Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

  2024cites this paper
• Nitroxidative stress in human neural progenitor cells: In situ measurement of nitric oxide/peroxynitrite imbalance using metalloporphyrin nanosensors.

  2024cites this paper
• Molecular mechanism underlying effect of D93 and D289 protonation states on inhibitor-BACE1 binding: exploration from multiple independent Gaussian accelerated molecular dynamics and deep learning

  2024cites this paper
• Production of a heterozygous exon skipping model of common marmosets using gene-editing technology

  2024cites this paper
• Olfactory Dysfunction and Alzheimer’s Disease: A Review

  2024cites this paper
• Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications

  2024cites this paper
• Synthesis and mechanistic study of Aβ42 C-terminus domain derived tetrapeptides that inhibit Alzheimer's Aβ-aggregation-induced neurotoxicity.

  2024cites this paper
• Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases

  2024cites this paper
• Copper(II) Can Kinetically Trap Arctic and Italian Amyloid-β40 as Toxic Oligomers, Mimicking Cu(II) Binding to Wild-Type Amyloid-β42: Implications for Familial Alzheimer’s Disease

  2024cites this paper
• Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease

  2024cites this paper
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

  2024cites this paper
• Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer’s Disease

  2024cites this paper
• Alzheimer's disease and sleep disorders: a bidirectional relationship.

  2024cites this paper
• Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease

  2024cites this paper
• Cortical neurodegeneration caused by Psen1 mutations is independent of Aβ

  2024influential citation
• A Combinational Therapy for Preventing and Delaying the Onset of Alzheimer’s Disease: A Focus on Probiotic and Vitamin Co-Supplementation

  2024cites this paper
• Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease.

  2023cites this paper
• The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?

  2023cites this paper
• Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease.

  2023cites this paper
• The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview

  2023cites this paper
• Membrane lipid remodeling modulates γ-secretase processivity.

  2023cites this paper
• The Future of Precision Medicine in the Cure of Alzheimer’s Disease

  2023influential citation
• Predicting Neurodegenerative Disease Using Prepathology Gut Microbiota Composition: a Longitudinal Study in Mice Modeling Alzheimer’s Disease Pathologies

  2023cites this paper
• Imaging Amyloid‐β Membrane Interactions: Ion‐Channel Pores and Lipid‐Bilayer Permeability in Alzheimer's Disease

  2023cites this paper
• Sleep fragmentation affects glymphatic system through the different expression of AQP4 in wild type and 5xFAD mouse models

  2023cites this paper
• Imaging Amyloid‐β Membrane Interactions: Ion‐Channel Pores and Lipid‐Bilayer Permeability in Alzheimer's Disease

  2023cites this paper
• The amyloid-β peptide: Guilty as charged?

  2023cites this paper
• Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies

  2023cites this paper
• Nascent Aβ42 Fibrillization in Synaptic Endosomes Precedes Plaque Formation in a Mouse Model of Alzheimer's-like β-Amyloidosis

  2023cites this paper
• Deciphering the Role of Selenoprotein M

  2023cites this paper
• Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions

  2023cites this paper
• Alzheimer’s Disease and Different Types of Cancer Likelihood: Unveiling Disparities and Potential Protective Effects in a Korean Cohort Study

  2023cites this paper
• Targeting Various Pathogenic Pathways for the Development of Antialzheimer's Drugs: An Update.

  2023cites this paper
• An Alternative View of Familial Alzheimer’s Disease Genetics

  2023cites this paper
• Regulation of Ryanodine Receptor-Dependent Neurotransmitter Release by AIP, Calstabins, and Presenilins.

  2023cites this paper
• Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition

  2023cites this paper
• Emerging diagnostics and therapeutics for Alzheimer disease

  2023cites this paper
• Evaluating the Clinical Significance of Diazepam Binding Inhibitor in Alzheimer’s Disease: A Comparison with Inflammatory, Oxidative, and Neurodegenerative Biomarkers

  2023cites this paper
• Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease

  2023cites this paper
• Getting ahead of Alzheimer’s disease: early intervention with focused ultrasound

  2023cites this paper
• Global Energy Metabolism Deficit in Alzheimer Disease Brain

  2023cites this paper
• Behavioral and metabolic and effects of ABCG4 KO in the APPswe,Ind (J9) mouse model of Alzheimer’s disease

  2023cites this paper
• Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials

  2023cites this paper
• WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective

  2023cites this paper